| Double-blind, placebo-controlled, randomized, two-cohort phase III study to evaluate AZD5305 A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) |
This is a research project to determine whether the study drug “AZD5305”, given in combination with a new hormonal agent (enzalutamide, abiraterone or darolutamide), is more effective in treating the type of cancer you have been diagnosed with than a new hormonal agent given alone.
Stade de la Maladie: Avancé ou métastatique
Organe: Prostate
Maladie: Cancer de la prostate mCRPC
